Hemostatic Closure of Femoral Artery Access Site, Using the QuickClose

NCT ID: NCT00507013

Last Updated: 2008-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2007-09-30

Brief Summary

The QuickClose study is a prospective, non-randomized study, to evaluate the safety and efficacy of the QuickClose device using two different dose types of heat exposure.

Patients undergoing a diagnostic angiogram procedure will be treated with the QuickClose device. Two groups of 20 patients each, will be enrolled consecutively, Group A will complete enrollment before enrollment into Group B begins. Patients will be monitored until 30 days after the procedure

Detailed Description

The primary safety endpoint is the incidence of major complications related to method for achieving hemostasis at the puncture site. The secondary safety endpoint is the incidence of minor complications related to method for achieving hemostasis at the puncture site. The primary efficacy endpoint are time to hemostasis, time to ambulation and time to discharge . The secondary efficacy endpoints are device and procedure success.

Conditions

Hemostasis,Surgical

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

2

Group Type: OTHER

QuickClose device

Intervention Type: DEVICE

Interventions

QuickClose device

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. The patient must be ≥ 18 years of age

2. The patient or guardian must provide written informed consent

3. The patient must be willing to comply with follow-up requirements

4. The patient has no child bearing potential or has a negative pregnancy test within the previous 7 days.

5. Patient is eligible for same day discharge

Procedural Inclusion:

1. A intravascular procedure was preformed using 6 Fr introducer

2. The introducer sheath is located in the common femoral artery

Exclusion Criteria

1. Manual compression has been preformed on the ipsilateral arterial site within the previous 6 weeks

2. Any closure device has been used on the ipsilateral arterial site within the previous 180 days

3. Any reentry of the ipsilateral site is planned within the next 6 weeks.

4. History of surgical repair of blood vessels of the ipsilateral arterial site

5. Significant bleeding diathesis or platelet dysfunction

1. Thrombocytopenia (Plt count ≤ 100,000)

2. Anemia (Hgb ≤ 10mg/dl and/or Hct ≤ 30mg/dl)

6. Has life expectancy of less than 1 year due to terminal illness

7. Currently being treated for an infection

8. Receiving GP 2b/3a inhibitors or requires warfarin therapy within the last 14 days.

9. INR results > 1.2 on day of procedure

10. Experienced a Myocardial infarction (CK-MB ≥ 2x upper limits of normal) within the previous 72 hours

11. Received thrombolytic within previous 72 hours

12. Patient is currently enrolled in an investigational device or drug study which endpoints have not been met.

13. Absent of pedal pulse

14. Pre-existing autoimmune disease (i.e., Lupus, Addison's Disease, Grave's Disease)

15. Has Body Mass Index(BMI) <20, or BMI >40

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sheba Medical Center

OTHER_GOV

Sponsor Role: collaborator

CardioDex

INDUSTRY

Sponsor Role: lead

Principal Investigators

Amit Segev, MD

Role: PRINCIPAL_INVESTIGATOR

The Chaim Sheba Medical Center

Locations

The Chaim Sheba M.C.

Tel Litwinsky, , Israel

Countries

Israel

Other Identifiers

RD 392-03

Identifier Type: -

Identifier Source: org_study_id